For example, calcimimetics (CaSR activators) are used to treat hyperparathyroidism while negative allosteric modulators (calcilytics, e.g., NPS2143) target genetic hypocalcemia disorders (Hannan et al., 2017; Nemeth et al., 2018). This evidence concerns the gene CASR and hyperparathyroidism.